CREME AI and CRISPR in tandem

CREME is a new AI-powered virtual laboratory invented by Cold Spring Harbor Laboratory (CSHL) Assistant Professor Peter Koo and his team. It allows geneticists to run thousands of virtual experiments with the click of a button. Now, scientists can use it to begin identifying and understanding key regions of the genome.

The program is modeled after CRISPR interference (CRISPRi), a genetic perturbation technique based on CRISPR. CRISPRi allows biologists to turn down the activity of specific genes in a cell. CREME lets scientists make similar changes in the virtual genome and predicts their effects on gene activity. In other words, it's almost like an AI version of CRISPRi.

"In reality, CRISPRi is incredibly challenging to perform in the laboratory. And you're limited by the number of perturbations and the scale. But since we're doing all our perturbations [virtually], we can push the boundaries. And the scale of experiments that we performed is unprecedented -- hundreds of thousands of perturbation experiments," explains Koo.

Koo and his team tested CREME on another AI-powered genome analysis tool called Enformer. They wanted to know how Enformer's algorithm makes predictions about the genome. Questions like that are central to Koo's work, he says.

"We have these big, powerful models. They're quite compelling at taking DNA sequences and predicting gene expression. But we don't really have any good ways of trying to understand what these models are learning. Presumably, they're making accurate predictions because they've learned a lot of the rules about gene regulation, but we don't actually know what their predictions are based off of."

With CREME, Koo's team uncovered a series of genetic rules that Enformer learned while analyzing the genome. That insight may one day prove invaluable for drug discovery. "Understanding the rules of gene regulation gives you more options for tuning gene expression levels in precise and predictable ways," says Koo.

With further fine-tuning, CREME may soon set geneticists on the path to discovering new therapeutic targets. Perhaps most impactfully, it may even give scientists who do not have access to a real laboratory the power to make these breakthroughs.